DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Primary progressive aphasia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePrimary progressive aphasia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for primary progressive aphasia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
No drug treatment for primary progressive aphasia is tested or reported in these abstracts. The 2024 expert opinion paper states that for aphasia generally — including vascular and neurodegenerative causes — there is still no clear-cut answer on whether pharmacotherapy is effective, and calls for further research with greater emphasis on language deficits and the use of biomarkers for personalised treatment. A 1990 review notes that clinical reports since the 1940s suggest some aphasic symptoms may improve after pharmacological therapy, and that early studies from the Boston VA Medical Center indicated the dopamine agonist bromocriptine might be a potentially useful agent, but it explicitly states that double-blind, placebo-controlled trials are needed to confirm or refute efficacy. No such trials are described in the provided abstracts.
The remaining abstracts address diagnosis, classification, and non-pharmacological management. A 2023 review of primary progressive aphasia poses six unanswered questions, including how many syndromes exist, whether syndromic diagnosis is useful, and how the disease can best be treated; it proposes that linking proteinopathies to phenotypes may guide effective therapies but does not report any treatment trial. A 2002 review describes advances in understanding the neural basis of semantic dementia and progressive non-fluent aphasia, noting that imaging confirms temporal atrophy and that computational models have advanced interpretations, but it does not test any intervention. A 1995 study examines two approaches to early aphasia therapy but concerns acute post-stroke aphasia, not primary progressive aphasia. A 2024 qualitative study of people with chronic post-stroke aphasia and their partners identifies five themes influencing maintenance of therapy gains, including beliefs about change, personal abilities, external support, real-life communication, and knowledge and service gaps; participants reported limited understanding of how to maintain gains and a lack of services to support this.
What is still missing for primary progressive aphasia: no completed or ongoing drug trial is described in these abstracts; no biomarker- or proteinopathy-stratified treatment study is reported; no funding for such trials is mentioned; and no consensus on which clinical syndrome definition or outcome measure should be used in a pharmacotherapy trial has been reached.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Neurology · 2002 · 30 citations
Progressive aphasic syndromes: clinical and theoretical advances
AbstractPURPOSE OF REVIEW: Knowledge of the neural basis for language and related aspects of cognition has been advanced through detailed studies of patients with primary progressive aphasia. This brief review highlights some recent work. RECENT FINDINGS: The impairment of semantic knowledge in patients with semantic dementia appears to influence performance in a wide variety of linguistic and cognitive domains, including morphological agreements such as the irregular past tense. Computational studies modeling the deficits of these patients have advanced interpretations of the impairments in semantic dementia. Imaging analyses have confirmed the presence of temporal atrophy cross-sectionally and longitudinally in these patients. In patients with semantic dementia, it appears that both the left temporal and right temporal regions contribute in different proportions to naming and comprehension, although the nature of the process underlying the consolidation of knowledge in semantic memory continues to be actively debated. In patients with progressive non-fluent aphasia, recent work has emphasized an impairment with verbs. Functional neuroimaging work with progressive non-fluent aphasics, compared directly to non-aphasic patients with frontotemporal dementia, has demonstrated a dissociation for grammatical and working memory aspects of sentence processing within the left frontal cortex. SUMMARY: These findings will improve diagnostic accuracy, prognostic ability, and therapeutic potential in patients with progressive aphasia.
The language recovery of acutely aphasic patients receiving different therapy regimens
AbstractHaving determined the efficacy of aphasia therapy and the importance of early intervention, the next step to take in aphasia treatment research is ‘to accumulate clinical research designed to test hypotheses on the relative effectiveness of various approaches to treatment’ (LaPointe 1984, p. 307). Following LaPointe's advice this study examined two approaches to early aphasia treatment by further analysing data collected by Holland and colleagues (1983).
The pharmacotherapy of aphasia: Historical perspective and directions for future research
AbstractClinical reports dating to the 1940s suggest that some aphasic symptoms may improve after pharmacological therapy. Recent studies from the Aphasia Research Center of the Boston VA Medical Center suggest that the dopamine agonist, bromocriptine, may be a potentially useful agent in the treatment of aphasia. At least two different hypotheses can be put forward to justify the use of dopamine agents in aphasia therapy. However, double-blind, placebo-controlled trials of pharmacological agents are needed to confirm or refute the efficacy of pharmacotherapy in the treatment of aphasia.
Expert Review of Neurotherapeutics · 2024 · 2 citations
Are pharmacotherapeutics effective for treating aphasia?
AbstractINTRODUCTION: Aphasia is a communication disorder resulting from stroke and/or neurodegenerative conditions which involve the left cerebral hemisphere. It is a debilitating disorder affecting a person's ability to speak, understand, read, and write. Its impact on daily life necessitates therapeutic strategies to aid patients with aphasia. AREAS COVERED: In this special report, the authors speculate whether current pharmacotherapeutic strategies are effective in treating aphasia. The authors look at aphasia caused by different conditions and how this could impact therapy before providing the reader with their expert perspectives. The aim of this paper is for the reader to gain a clearer understanding of the efficacy of the current pharmacotherapeutic treatment paradigms as well as potential future developments. EXPERT OPINION: The exploration of pharmacotherapy for aphasia in vascular brain disorders and neurodegenerative diseases has received much attention in recent years with various therapeutic strategies having been put forward. In terms of whether pharmacotherapy is effective for the treatment of aphasia, there is still no clear-cut answer. Further research is needed with more studies requiring a greater emphasis on language and communication deficits. Biomarkers may also help clinicians provide their patients with a more personalized treatment plan.
<i>“I’ve Got No Skills to Maintain – to Keep That Going”</i> : A Qualitative Study of People with Chronic Aphasia and Their Partners About Factors Contributing to the Maintenance of Aphasia Therapy Gains
AbstractBackground The maintenance of therapy gains is critical for successful aphasia rehabilitation, a topic often overlooked in both research and clinical practice. For some people with chronic aphasia, maintaining therapeutic gains can be challenging, potentially resulting in diminished communicative function over time. Furthermore, maintaining therapy gains may necessitate consistent, deliberate effort; however, little is known about the factors supporting this process. People living with chronic aphasia and their family members may provide critical insights into the behavioural factors that impact the maintenance of therapy gains. Understanding these factors will be crucial for developing long-lasting, effective aphasia interventions.Aim In this study, we explored the perspectives and practices of people with chronic aphasia and their partners concerning the maintenance of gains from therapy for post-stroke chronic aphasia.Methods & Procedures Eight in-depth, semi-structured interviews were conducted, involving four people with chronic aphasia and four partners. We employed inductive thematic data analysis to identify emergent themes.Outcomes & Results Five themes were identified that were perceived to influence the maintenance of gains made during aphasia rehabilitation. These were: 1) Beliefs about change: improvement, decline, and maintenance; 2) Personal abilities impact improvement and maintenance; 3) External support impacts improvement and maintenance; 4) Engaging in ongoing real-life communication impacts improvement and maintenance; and 5) Knowledge and services gaps in maintenance. The findings demonstrate the complexity and interaction of factors that potentially facilitate or hinder the maintenance of therapy gains in chronic aphasia.Conclusions People with chronic aphasia and their partners report having a limited understanding of the necessity and methods for maintaining therapy gains. They also describe a lack of services to support this. A lack of knowledge and services could hinder the ability to maintain therapeutic benefits. Our study also suggests various behavioural factors are involved in maintaining gains. Forming meaningful real-life communication routines may potentially optimise such gains. These findings highlight the necessity of placing maintenance at the heart of aphasia rehabilitation, informing future interventions and service development.
Greater South Information System · 2023 · 0 citations · open access
Primary progressive aphasia: six questions in search of an answer
AbstractHere, we review recent progress in the diagnosis and management of primary progressive aphasia-the language-led dementias. We pose six key unanswered questions that challenge current assumptions and highlight the unresolved difficulties that surround these diseases. How many syndromes of primary progressive aphasia are there-and is syndromic diagnosis even useful? Are these truly 'language-led' dementias? How can we diagnose (and track) primary progressive aphasia better? Can brain pathology be predicted in these diseases? What is their core pathophysiology? In addition, how can primary progressive aphasia best be treated? We propose that pathophysiological mechanisms linking proteinopathies to phenotypes may help resolve the clinical complexity of primary progressive aphasia, and may suggest novel diagnostic tools and markers and guide the deployment of effective therapies.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
